SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 424B3 - Prospectus [Rule 424(b)(3)]:
SEC Accession No. 0001213900-24-059612
Filing Date
2024-07-08
Accepted
2024-07-05 18:40:25
Documents
13

Document Format Files

Seq Description Document Type Size
1 PROSPECTUS ea0209030-424b3_cerotherap.htm 424B3 3018971
2 GRAPHIC image_001.jpg GRAPHIC 12454
3 GRAPHIC image_002.jpg GRAPHIC 31479
4 GRAPHIC image_003.jpg GRAPHIC 155502
5 GRAPHIC image_004.jpg GRAPHIC 45401
6 GRAPHIC image_005.jpg GRAPHIC 120344
7 GRAPHIC image_006.jpg GRAPHIC 107565
8 GRAPHIC image_007.jpg GRAPHIC 69635
9 GRAPHIC image_008.jpg GRAPHIC 64189
10 GRAPHIC image_009.jpg GRAPHIC 92156
11 GRAPHIC image_010.jpg GRAPHIC 37456
12 GRAPHIC image_011.jpg GRAPHIC 43747
13 GRAPHIC image_012.jpg GRAPHIC 82093
  Complete submission text file 0001213900-24-059612.txt   4208975
Mailing Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080 650-407-2376
CERO THERAPEUTICS HOLDINGS, INC. (Filer) CIK: 0001870404 (see all company filings)

IRS No.: 871088814 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B3 | Act: 33 | File No.: 333-279156 | Film No.: 241103193
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)